521 related articles for article (PubMed ID: 18250343)
1. Baseline prostate-specific antigen level and risk of prostate cancer and prostate-specific mortality: diagnosis is dependent on the intensity of investigation.
Connolly D; Black A; Gavin A; Keane PF; Murray LJ
Cancer Epidemiol Biomarkers Prev; 2008 Feb; 17(2):271-8. PubMed ID: 18250343
[TBL] [Abstract][Full Text] [Related]
2. Prostate cancer mortality in screen and clinically detected prostate cancer: estimating the screening benefit.
van Leeuwen PJ; Connolly D; Gavin A; Roobol MJ; Black A; Bangma CH; Schröder FH
Eur J Cancer; 2010 Jan; 46(2):377-83. PubMed ID: 19804966
[TBL] [Abstract][Full Text] [Related]
3. Baseline prostate-specific antigen compared with median prostate-specific antigen for age group as predictor of prostate cancer risk in men younger than 60 years old.
Loeb S; Roehl KA; Antenor JA; Catalona WJ; Suarez BK; Nadler RB
Urology; 2006 Feb; 67(2):316-20. PubMed ID: 16442597
[TBL] [Abstract][Full Text] [Related]
4. Prostate-specific antigen recurrence and mortality after conventional dose radiation therapy in select men with low-risk prostate cancer.
Petit JH; Chen MH; Loffredo M; Sussman B; Renshaw AA; D'Amico AV
Cancer; 2006 Nov; 107(9):2180-5. PubMed ID: 17009323
[TBL] [Abstract][Full Text] [Related]
5. Prostate-specific antigen velocity and the detection of gleason score 7 to 10 prostate cancer.
Punglia RS; Cullen J; McLeod DG; Chen Y; D'Amico AV
Cancer; 2007 Nov; 110(9):1973-8. PubMed ID: 17886252
[TBL] [Abstract][Full Text] [Related]
6. Possibility of re-screening intervals of more than one year in men with PSA levels of 4.0 ng/ml or less.
Ito K; Yamamoto T; Ohi M; Takechi H; Kurokawa K; Suzuki K; Yamanaka H
Prostate; 2003 Sep; 57(1):8-13. PubMed ID: 12886518
[TBL] [Abstract][Full Text] [Related]
7. The utility of prostate-specific antigen velocity thresholds in clinical practice: a population-based analysis.
Connolly D; Black A; Murray LJ; Nambirajan T; Keane PF; Gavin A
BJU Int; 2008 Jun; 101(12):1507-12. PubMed ID: 18341627
[TBL] [Abstract][Full Text] [Related]
8. Global update on defining and treating high-risk localized prostate cancer with leuprorelin: a USA perspective--identifying men at diagnosis who are at high risk of prostate cancer death after surgery or radiation therapy.
D'Amico A
BJU Int; 2007 Jan; 99 Suppl 1():13-6; discussion 17-8. PubMed ID: 17229162
[TBL] [Abstract][Full Text] [Related]
9. Prostate carcinoma detection and increased prostate-specific antigen levels after 4 years in Dutch and Japanese males who had no evidence of disease at initial screening.
Ito K; Raaijmakers R; Roobol M; Wildhagen M; Yamanaka H; Schröder FH
Cancer; 2005 Jan; 103(2):242-50. PubMed ID: 15578715
[TBL] [Abstract][Full Text] [Related]
10. Screening for prostate cancer: updated experience from the Tyrol study.
Horninger W; Berger A; Pelzer A; Klocker H; Oberaigner W; Schönitzer D; Severi G; Robertson C; Boyle P; Bartsch G
Can J Urol; 2005 Feb; 12 Suppl 1():7-13; discussion 92-3. PubMed ID: 15780158
[TBL] [Abstract][Full Text] [Related]
11. Longitudinal PSA changes in men with and without prostate cancer: assessment of prostate cancer risk.
Berger AP; Deibl M; Steiner H; Bektic J; Pelzer A; Spranger R; Klocker H; Bartsch G; Horninger W
Prostate; 2005 Aug; 64(3):240-5. PubMed ID: 15712213
[TBL] [Abstract][Full Text] [Related]
12. Prostate specific-antigen distribution in asymptomatic Canadian men with no clinical evidence of prostate cancer.
Chun FK; Perrotte P; Briganti A; Benayoun S; Lebeau T; Ramirez A; Lewinshtein DJ; Valiquette L; Guay JP; Karakiewicz PI
BJU Int; 2006 Jul; 98(1):50-3. PubMed ID: 16831142
[TBL] [Abstract][Full Text] [Related]
13. 4-year prostate specific antigen progression and diagnosis of prostate cancer in the European Randomized Study of Screening for Prostate Cancer, section Rotterdam.
Schröder FH; Raaijmakers R; Postma R; van der Kwast TH; Roobol MJ
J Urol; 2005 Aug; 174(2):489-94; discussion 493-4. PubMed ID: 16006878
[TBL] [Abstract][Full Text] [Related]
14. The Prostate cancer Intervention Versus Observation Trial:VA/NCI/AHRQ Cooperative Studies Program #407 (PIVOT): design and baseline results of a randomized controlled trial comparing radical prostatectomy to watchful waiting for men with clinically localized prostate cancer.
Wilt TJ; Brawer MK; Barry MJ; Jones KM; Kwon Y; Gingrich JR; Aronson WJ; Nsouli I; Iyer P; Cartagena R; Snider G; Roehrborn C; Fox S
Contemp Clin Trials; 2009 Jan; 30(1):81-7. PubMed ID: 18783735
[TBL] [Abstract][Full Text] [Related]
15. Prostate specific antigen changes as related to the initial prostate specific antigen: data from the prostate, lung, colorectal and ovarian cancer screening trial.
Crawford ED; Pinsky PF; Chia D; Kramer BS; Fagerstrom RM; Andriole G; Reding D; Gelmann EP; Levin DL; Gohagan JK
J Urol; 2006 Apr; 175(4):1286-90; discussion 1290. PubMed ID: 16515981
[TBL] [Abstract][Full Text] [Related]
16. Prostate-specific antigen levels in the United States: implications of various definitions for abnormal.
Welch HG; Schwartz LM; Woloshin S
J Natl Cancer Inst; 2005 Aug; 97(15):1132-7. PubMed ID: 16077071
[TBL] [Abstract][Full Text] [Related]
17. Prostate-specific antigen (PSA) and PSA velocity for prostate cancer detection in men aged <50 years.
Sun L; Moul JW; Hotaling JM; Rampersaud E; Dahm P; Robertson C; Fitzsimons N; Albala D; Polascik TJ
BJU Int; 2007 Apr; 99(4):753-7. PubMed ID: 17244286
[TBL] [Abstract][Full Text] [Related]
18. Is additional testing necessary in men with prostate-specific antigen levels of 1.0 ng/mL or less in a population-based screening setting? (ERSPC, section Rotterdam).
Roobol MJ; Roobol DW; Schröder FH
Urology; 2005 Feb; 65(2):343-6. PubMed ID: 15708050
[TBL] [Abstract][Full Text] [Related]
19. Identification of clinically significant prostate cancer by prostate-specific antigen screening.
Smith RP; Malkowicz SB; Whittington R; VanArsdalen K; Tochner Z; Wein AJ
Arch Intern Med; 2004 Jun; 164(11):1227-30. PubMed ID: 15197049
[TBL] [Abstract][Full Text] [Related]
20. A model of prostate-specific antigen screening outcomes for low- to high-risk men: information to support informed choices.
Howard K; Barratt A; Mann GJ; Patel MI
Arch Intern Med; 2009 Sep; 169(17):1603-10. PubMed ID: 19786680
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]